VIDEO: No benefit from radiotherapy after chemoimmunotherapy for rare B-cell lymphoma
Click Here to Manage Email Alerts
In this video, Joshua Brody, MD, discusses the results of the IELSG37 randomized trial, which examined whether radiotherapy is necessary after front-line chemoimmunotherapy for patients with primary mediastinal B-cell lymphoma.
The results of the large trial, which were presented at ASCO Annual Meeting, indicated that radiotherapy in this setting showed no benefit for patients, Brody, director of the lymphoma immunotherapy program at Mount Sinai's Tisch Cancer Institute, said.
Brody said the chemoimmunotherapy administered varied amongst the groups. "It was not mandated by the protocol. Overall, only a minority — less than one out of five patients — got what in the United States is the most common regimen; the dose adjusted R-EPOCH. The remainder either got standard R-CHOP or dose-intensified versions of R-CHOP," he said.
The PFS after 30 months was extremely close between the two arms — 98.5% in the radiotherapy arm and 96.2% in the observation arm.
"Those slight differences are not statistically significant by any metric," Brody said.
Reference :
- Zucca E, et al. Abstract LBA7505. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Read more about
Click Here to Manage Email Alerts